Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFR?ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 
Sutro Biopharma and Boehringer Ingelheim BioXcellence(TM) collaboration: Established first-in-class cell-free capabilities at commercial scale

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.